Journal of Experimental Medicine

jem.org

02 July 2026 18:42

Leveraging cDC1 biology and function for enhanced #immunotherapy. New review from Ross W. Ward, Uddipan Kar, Sreekumar Balan, and Nina Bhardwaj @bhardwajlab.bsky.social (Icahn School of Medicine at Mount Sinai): rupress.org/jem/article/... #CancerFocus #TumorImmunology #InnateImmunity #inflammation

Journal of Experimental Medicine

jem.org

10 June 2026 16:56

Ward, Kar, Balan, and Bhardwaj @bhardwajlab.bsky.social review how conventional type 1 #DendriticCells (cDC1s) coordinate antitumor immunity through cross-presentation, immune cell networking, and spatial organization in tumors. rupress.org/jem/article/... #CancerFocus #Immunotherapy

Waggoner Lab

labwaggoner.bsky.social

16 April 2026 15:10

Type 1 IFN primes cross-dressing of cDCs with peptide–MHC-I complexes from non-haematopoietic cells, explaining ability of mRNA vaccines to activate CD8+ T cells against antigens not encoded by the vaccine @nature.com @washumedicine.bsky.social #Murphy www.nature.com/articles/s41...

The Drew Weissman Lab

drewweissmanlab.bsky.social

06 April 2026 14:32

New article! 👏One-component ionizable amphiphilic Janus dendrimers as a delivery platform for efficient mRNA vaccine development | Science Advances www.science.org/doi/10.1126/...

UT MD Anderson Cancer Center

mdanderson.bsky.social

01 April 2026 18:04

Researchers from UT MD Anderson developed a first-in-class antibody that targets a protein over expressed in many cancer types, allowing for the creation of a new treatment that brings targeted radiation directly to tumor cells. Learn more: spr.ly/6013B6o6uJ #OncSky #EndCancer